Skip Page Header

Home > Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees.

Dolan, Kate and Wirtz, Andrea L and Moazen, Babak and Ndeff o-mbah, Martial and Galvani, Alison and Kinner, Stuart A and Courtney, Ryan and McKee, Martin and Amon, Joseph J and Maher, Lisa and Hellard, Margaret and Beyrer, Chris and Altice, Frederick (2016) Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. The Lancet, 388, (10049), .

External website: http://www.thelancet.com/series/aids-2016


The prison setting presents not only challenges, but also opportunities, for the prevention and treatment of HIV, viral hepatitis, and tuberculosis. We did a comprehensive literature search of data published between 2005 and 2015 to understand the global epidemiology of HIV, hepatitis C virus (HCV), hepatitis B virus (HBV), and tuberculosis in prisoners. We further modelled the contribution of imprisonment and the potential impact of prevention interventions on HIV transmission in this population. Of the estimated 10·2 million people incarcerated worldwide on any given day in 2014, we estimated that 3·8% have HIV (389 000 living with HIV), 15·1% have HCV (1 546 500), 4·8% have chronic HBV (491 500), and 2·8% have active tuberculosis (286 000). The few studies on incidence suggest that intraprison transmission is generally low, except for large-scale outbreaks. Our model indicates that decreasing the incarceration rate in people who inject drugs and providing opioid agonist therapy could reduce the burden of HIV in this population. The prevalence of HIV, HCV, HBV, and tuberculosis is higher in prison populations than in the general population, mainly because of the criminalisation of drug use and the detention of people who use drugs. The most eff ective way of controlling these infections in prisoners and the broader community is to reduce the incarceration of people who inject drugs.

Repository Staff Only: item control page